Current Study: A7

Purpose:
• The overall purpose of this study is to find out if the study drug is absorbed or eliminated differently in participants with normal liver function compared to participants with impaired liver function. Another purpose is to assess the safety and tolerability of the drug in people with healthy to impaired liver function.
• This study is for research purposes only and is not intended to treat your liver disease.

Method of Administration: Single oral dose of the investigational drug

Investigator: Thomas Marbury, MD

To qualify:
• 18 to 75 years old
• Must have decreased liver function or disease such as fatty liver disease (NASH), Hepatitis C (if successfully treated), past history of alcohol related liver disease or cirrhosis
• Volunteers may be taking medicines such as spironolactone (Aldactone®), furosemide (Lasix®), lactulose, or rifaximin (Xifaxan®)
• May also have ascites (fluid in your abdomen) or encephalopathy (brain condition that causes irritability or trouble sleeping)

Length/Duration:
• 1 eligibility screening visit
• Consecutive 5 days and 4 nights in our research facility
• 1 follow-up visit

Location: 5055 South Orange Avenue, Orlando, FL 32809

Compensation:
Qualified participants will receive study drug, study related physical exams and laboratory tests
Qualified participants will be compensated up to $2,575 for time and travel

Whom to Contact Recruitment Department: 407-240-7876